NRXPW
Price:
$0.0731
Market Cap:
$17.52M
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.[Read more]
Industry
Biotechnology
IPO Date
2017-12-01
Stock Exchange
NASDAQ
Ticker
NRXPW
According to NRx Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.01. This represents a change of -99.88% compared to the average of -8.43 of the last 4 quarters.
The mean historical PE Ratio of NRx Pharmaceuticals, Inc. over the last ten years is 99.37. The current -0.01 PE Ratio has changed -101.01% with respect to the historical average. Over the past ten years (40 quarters), NRXPW's PE Ratio was at its highest in in the June 2020 quarter at 9.15K. The PE Ratio was at its lowest in in the June 2018 quarter at -9723.06.
Average
99.37
Median
-20.72
Minimum
-677.26
Maximum
1.38K
Discovering the peaks and valleys of NRx Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = 1.38K
Minimum Annual Increase = -1753.85%
Minimum Annual PE Ratio = -677.26
Year | PE Ratio | Change |
---|---|---|
2023 | -1.16 | -94.42% |
2022 | -20.72 | -33.75% |
2021 | -31.27 | -95.38% |
2020 | -677.26 | -612.85% |
2019 | 132.06 | -90.41% |
2018 | 1.38K | -1753.85% |
The current PE Ratio of NRx Pharmaceuticals, Inc. (NRXPW) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-17.72
5-year avg
-119.67
10-year avg
99.37
NRx Pharmaceuticals, Inc.’s PE Ratio is greater than NRx Pharmaceuticals, Inc. (-0.69), greater than Relief Therapeutics Holding AG (-0.58), greater than Quantum-Si incorporated (-1.45), less than eFFECTOR Therapeutics, Inc. (-0.00), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.10),
Company | PE Ratio | Market cap |
---|---|---|
-0.69 | $17.52M | |
-0.58 | $23.68M | |
-1.45 | $134.38M | |
-0.00 | $17.41K | |
-1.10 | $42.03M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NRx Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NRx Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is NRx Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for NRx Pharmaceuticals, Inc. (NRXPW)?
What is the highest PE Ratio for NRx Pharmaceuticals, Inc. (NRXPW)?
What is the 3-year average PE Ratio for NRx Pharmaceuticals, Inc. (NRXPW)?
What is the 5-year average PE Ratio for NRx Pharmaceuticals, Inc. (NRXPW)?
How does the current PE Ratio for NRx Pharmaceuticals, Inc. (NRXPW) compare to its historical average?